关键词：慢性阻塞性肺病；支气管扩张；肺部限制气流；提高呼吸困难
摘 要：COPD covers various progressive lung diseases including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis. It is a serious condition that restricts airflow in the lungs and is characterized by increasing breathlessness. The exact etiology of COPD is not understood; however, most cases of COPD are caused by genetic factors and by inhaling pollutants such as smoking, fumes, and chemicals. As the disease develops, the symptoms tend to get worse if an infection occurs in the lungs. While the disease cannot be cured, it can be managed and treated.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

07. Management of COPD

07.1 Five Forces Analysis

08. Market Segmentation by Types of Treatment

09. Geographical Segmentation

09.1 COPD Market in Americas

09.1.1 Market Size and Forecast

09.2 COPD Market in EMEA Region

09.2.1 Market Size and Forecast

09.3 COPD Market in APAC Region

09.3.1 Market Size and Forecast

10. Rate of Incidence and Prevalence

10.1.1 US

10.1.2 Europe

10.1.3 Asia

11. Pipeline Snapshot

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

19.1 Competitive Scenario

19.1.1 Key News

19.1.2 Mergers and Acquisitions

19.2 Market Share Analysis 2013

19.3 Other Prominent Vendors

20. Key Vendor Analysis

20.1 AstraZeneca

20.1.1 Key Facts

20.1.2 Business Description

Business 20.1.3 Segmentation

20.1.4 Business Strategy

20.1.5 Business Segmentation by Revenue

20.1.6 Business Segmentation by Revenue 2011-2013

20.1.7 Geographical Segmentation by Revenue 2013

20.1.8 Key Developments

20.1.9 SWOT Analysis

20.2 Boehringer Ingelheim

20.2.1 Key Facts

20.2.2 Business Overview

20.2.3 Business Segmentation by Revenue 2013

20.2.4 Business Segmentation by Revenue 2012 and 2013

20.2.5 Geographical Segmentation by Revenue 2013

20.2.6 Business Strategy

20.2.7 Recent Developments

20.2.8 SWOT Analysis

20.3 GlaxoSmithKline

20.3.1 Key Facts

20.3.2 Business Overview

20.3.3 Business Segmentation

20.3.4 Business Segmentation by Revenue 2012 and 2013

20.3.5 Geographical Segmentation by Revenue 2013

20.3.6 Pipeline Products

20.3.7 Business Strategy

20.3.8 Key Information

20.3.9 SWOT Analysis

20.4 Novartis

20.4.1 Key Facts

20.4.2 Business Overview

20.4.3 Business Segmentation by Revenue 2013

20.4.4 Business Segmentation by Revenue 2012 and 2013

20.4.5 Geographical Segmentation by Revenue 2013

20.4.6 Business Strategy

20.4.7 Key Developments

20.5 SWOT Analysis

20.6 Pfizer

20.6.1 Key Facts

20.6.2 Business Description

20.6.3 Business Segmentation

20.6.4 Business Segmentation by Revenue 2013

20.6.5 Business Segmentation by Revenue 2012 and 2013

20.6.6 Geographical Segmentation by Revenue 2013

20.6.7 Business Strategy

20.6.8 Key Developments

20.6.9 SWOT Analysis

21. Other Reports in this Series